Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up

Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

    Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus

    Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.

      Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

      Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

        AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up

        AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

          Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong

          Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.

            Will Radius Health (RDUS) Disappoint This Earnings Season?

            Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.

              Key Predictions for Q3 Earnings Reports of ABBV, MRK

              The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.

                Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More

                Four major biotech giants are set to report third-quarter results on Oct 26. A sneak preview as to how things are shaping up for these companies.

                  A Slew Of Q3 Earnings

                  A Slew Of Q3 Earnings

                    Mark Vickery headshot

                    Big Morning of Q3 Earnings Beats

                    Most major companies reporting before the opening bell today have outperformed expectations -- in some cases by a wide margin.

                      Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco

                      Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

                        Eli Lilly (LLY) Tops Q3 Earnings & Sales, Ups 2017 View

                        Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

                          Will Merck (MRK) Keep the Earnings Streak Alive in Q3?

                          Merck's (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q3. However, headwinds remain in the form genericization of key drugs and increasing competition.

                            Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS

                            The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling

                              Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.

                                Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

                                Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.

                                  Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

                                  Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.

                                    Novartis Reports Positive Results on Thrombocytopenia Drug

                                    Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.

                                      What to Expect from Big Pharmas After J&J's Solid Q3 Results?

                                      Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

                                        Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?

                                        Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                          Cancer Space Update: Lung & Breast Cancer Studies in Focus

                                          While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

                                            Lilly's Verzenio Gets Priority Review in First-Line Setting

                                            Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

                                              Arpita Dutt headshot

                                              Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

                                              Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

                                                IDEX (IEX) To Report Q3 Earnings: What's in the Cards?

                                                For the third quarter, IDEX's (IEX) revenues are likely to be affected by the volatility in the market as it procures substantial amount of raw materials and components from suppliers across the globe.

                                                  Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib

                                                  Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.